New discovery on the causes of PAP lung disease can also offer solutions for treating obesity and heart disease. The research group of Associate Professor Alexander Mildner at the University of Turku, Finland, identified a genetic defect that causes the accumulation of lipids in the pulmonary alveoli.
There are approximately 40 trillion cells in the human body and every one of them needs oxygen to survive. If the oxygen level drops, the cells must be able to sense the change and adapt to it. Sir Peter Ratcliffe discovered how this adaptation occurs. The discovery earned Ratcliffe and his associates the Nobel Prize in Physiology or Medicine in 2019. Ratcliffe visited the University of Turku 25 August.
Registration to BioCity Symposium is open until 11 August 2022. BioCity Symposium is one of the most important meetings in Turku region for researchers working in the fields of bio- and molecular medicine. This year the event is arranged together with InFLAMES Flagship with title Solution is in Immunity.
Professor of Cancer Biology at the University of Turku, InLAMES Flagship Director Jukka Westermarck has been nominated as a member of the European Association for Cancer Research (EACR) executive board. EACR is Europe's largest association promoting cancer research and has more than 10,000 members worldwide.
– Developing new diagnostic methods for detection and treatment of various diseases are key objectives of the InFLAMES Research Flagship. Collaboration with companies is invaluable to achieve this goal. The next InFLAMES Corporate Corner discusses on how the University and companies are already facilitating the cooperation and what more is needed, both from us and the diagnostics companies, to make the process even smoother” says InFLAMES Project Manager Kaisa Hakkila.
The new total-body PET scanner has been introduced at the Turku PET Centre. This new generation of medical imaging devices offers novel methods for studying diseases that affect the entire body, not only a single organ. Such diseases include diabetes, coronary artery disease, and multiple sclerosis. For the patient, being able to use the new device means a lower amount of radiation and a shorter scanning time.
Professor and Chief Physician, InFLAMES group leader Pirjo Nuutila is receiving the 2022 Novo Nordisk Foundation Lecture prize for her contribution to research on metabolic diseases such as overweight and diabetes.